Welcome to our dedicated page for SRX Health Solutions news (Ticker: SRXH), a resource for investors and traders seeking the latest updates and insights on SRX Health Solutions stock.
SRx Health Solutions, Inc. (NYSE American: SRXH) issues frequent press releases and SEC-referenced announcements that document its transition toward a digital-asset treasury operating model and its planned acquisition of EMJ Crypto Technologies Inc. (EMJX). The news flow provides insight into how the company is reshaping its strategy around a Gen2 digital-asset treasury platform that uses quantitative models, artificial intelligence and systematic risk controls.
Recent news items describe the definitive agreement to acquire EMJX, stockholder approval for a future name change to EMJX, Inc. and a planned ticker change to EMJX upon closing of the transaction. Company announcements also cover the deployment of an initial allocation of capital into digital assets such as Bitcoin and Ethereum, which the company characterizes as part of a measured, model-driven treasury management approach rather than short-term speculation.
Other SRXH news highlights enhancements to the EMJX platform, including integration of OpenAI large language models for research and risk decision support and the use of prediction-market probability data to strengthen its internal risk-intelligence framework. Governance and capital-markets updates appear regularly, such as the appointment of new directors with experience in cannabis, capital markets and cryptocurrency treasury strategies, amendments to the company’s charter to increase authorized shares, and private placements of preferred stock and warrants.
SRXH news releases also address NYSE American listing matters, including notifications of stockholders’ equity deficiencies and acceptance of the company’s plan to regain compliance with continued listing standards. For investors tracking SRXH, the news feed offers a consolidated view of transaction milestones, treasury activities, platform development and regulatory communications. Monitoring this page helps readers follow how the company’s proposed combination with EMJX progresses and how its digital-asset treasury strategy evolves over time.
SRx Health Solutions (NYSE American: SRXH) announced that on Dec. 30, 2025 it deployed an initial $10 million of capital into several digital assets, including Bitcoin and Ethereum, plus a select sleeve of high‑conviction tokens.
The Company said the purchases were executed using internally developed models intended to preserve long‑term optionality across volatile market regimes and that it will provide periodic updates on treasury operations while prioritizing operational execution and system development.
The company did not disclose asset‑level allocations or position sizes, citing its treasury management policies.
SRx Health Solutions (NYSE American: SRXH) and its treasury platform EMJX announced on Dec. 23, 2025 an expanded risk‑intelligence framework that adds event‑probability inputs from prediction‑market platforms including Polymarket.
The integration feeds market‑implied probabilities into EMJX’s QAM Engine to produce structured risk metrics such as an internal Event Volatility Score intended to inform hedging posture, exposure pacing, and capital‑allocation guardrails. The system will also evaluate signal reliability by comparing historical prediction‑market outcomes with realized volatility to refine model calibration and governance thresholds.
EMJX emphasizes it is a treasury operating system focused on survivability and long‑term capital compounding, using external data inside a governed, model‑driven risk framework.
SRx Health Solutions (NYSE American: SRXH) announced on Dec 19, 2025 that its EMJ Crypto Technologies unit (EMJX) is integrating OpenAI’s latest commercially available large language models into its Gen2 Digital Asset Treasury (Gen2 DAT) and proprietary QAM Engine.
The integration is intended to enhance research synthesis, retrieval-augmented analysis, and the incorporation of market, macroeconomic, and protocol-level data into portfolio construction, volatility management, and risk-management decision support while retaining human oversight and established quantitative controls.
SRx Health (NYSE American: SRXH) entered a definitive agreement to acquire EMJ Crypto Technologies (EMJX) to build a next-generation digital-asset treasury operating system. Closing is expected in Q1 2026, subject to SRx shareholder approval and customary closing conditions. Upon closing, Eric M. Jackson, Ph.D. is expected to serve as Chief Executive Officer and Chairman of the combined company. EMJX is described as a "Gen2" multi-asset, AI- and quantitative-driven treasury platform powered by a proprietary QAM Engine developed since 2021. The company says the platform emphasizes systematic risk management, hedging, and reinvestment of excess capital to reduce reliance on equity issuance. The board unanimously approved the transaction; a future name and ticker change are planned, subject to approvals.
SRx Health Solutions (NYSE American: SRXH) announced the appointment of Sammy Dorf, Esq. to its Board of Directors on November 10, 2025. Dorf is described as a seasoned dealmaker with nearly a decade of leadership at the intersection of cannabis, capital markets, and strategic development. His most recent role was Executive Chairman of Flora Growth Corp (NASDAQ: FLGC), where he guided a strategic transition into a crypto treasury company. The release highlights Dorf’s legal expertise, growth experience, and operational execution. The company included standard forward-looking statements and directed investors to its SEC filings for risk factors.
SRx Health Solutions (NYSE American: SRXH) said the NYSE American notified the company of unusual trading activity in its common shares on November 6, 2025. The company stated it is not aware of any material developments beyond what has been publicly disclosed and reminded investors to rely on its SEC filings and press releases. The release was issued pursuant to Section 401(d) of the NYSE American Company Guide and includes a standard forward-looking statements caution.
Contact information for CEO Kent Cunningham and investor relations via KCSA Strategic Communications is provided for further inquiries.
SRx Health Solutions (NYSE American: SRXH) received a notice from NYSE American that it does not meet Section 1003(a)(ii) continued listing standards because its stockholders' equity is below $4.0 million while reporting net losses in three of its four most recent fiscal years.
The company must submit a Plan by November 13, 2025 describing actions to regain compliance by the Plan Period Deadline of July 14, 2026. The notice does not have an immediate effect on listing or trading and does not change SEC reporting obligations.
SRx Health Solutions (NYSE American: SRXH) has announced the appointment of Joshua Epstein to its Board of Directors and Compensation Committee. The announcement represents a straightforward addition to the company's governance structure.
The press release primarily consists of standard forward-looking statements and contact information, with no additional details provided about Epstein's background, qualifications, or specific contributions expected in his new role.
SRx Health Solutions (NYSE American: SRXH) has announced the cancellation of an additional 350,000 shares, bringing the total shares canceled to over 19 million. The cancellation is part of a Settlement, Share Forfeiture and Mutual Release Agreement with certain founders and former officers of its Canadian subsidiary.
The forfeited shares were originally issued during the acquisition of SRx Canada. While the company has agreed to release specific claims against parties involved in the settlement, it maintains the right to pursue legal action against former SRx Canada officers who are not part of the agreement to recover stockholder value.
SRx Health Solutions (NYSE American: SRXH) has received a notice of non-compliance from NYSE American due to failing to file its Q2 2025 10-Q report by the August 19, 2025 deadline. The company has been granted an initial six-month cure period to file the delinquent report, with the possibility of an additional six-month extension at the Exchange's discretion.
While this notification does not immediately impact SRXH's stock listing or trading status, the company must address this filing delinquency to maintain its listing. Management states they are working with auditors to complete the filing and expects to submit the report before the cure period deadline.